Andra AP fonden Acquires 8,420 Shares of IDEXX Laboratories, Inc. $IDXX

Andra AP fonden raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,320 shares of the company’s stock after acquiring an additional 8,420 shares during the period. Andra AP fonden’s holdings in IDEXX Laboratories were worth $25,925,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Principal Securities Inc. grew its holdings in shares of IDEXX Laboratories by 15.7% during the fourth quarter. Principal Securities Inc. now owns 2,541 shares of the company’s stock worth $1,719,000 after purchasing an additional 345 shares during the last quarter. Great Lakes Advisors LLC grew its holdings in shares of IDEXX Laboratories by 1.5% during the fourth quarter. Great Lakes Advisors LLC now owns 4,277 shares of the company’s stock worth $2,894,000 after purchasing an additional 62 shares during the last quarter. Connecticut Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $253,000. Aviva PLC grew its holdings in shares of IDEXX Laboratories by 5.0% during the fourth quarter. Aviva PLC now owns 71,664 shares of the company’s stock worth $48,483,000 after purchasing an additional 3,382 shares during the last quarter. Finally, Great Valley Advisor Group Inc. grew its holdings in shares of IDEXX Laboratories by 19.8% during the fourth quarter. Great Valley Advisor Group Inc. now owns 599 shares of the company’s stock worth $405,000 after purchasing an additional 99 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $557.91 on Friday. The stock’s 50 day moving average is $563.14 and its 200 day moving average is $628.16. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $44.01 billion, a P/E ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the topic of several research reports. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus reduced their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup initiated coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Finally, UBS Group reduced their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.